AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Tonix Receives FDA Clearance for Phase 2 Trial of TNX-102 SL for Major Depressive Disorder.
ByAinvest
Wednesday, Dec 3, 2025 10:16 am ET1min read
Tonix Pharmaceuticals Holdings has received FDA clearance to launch a Phase 2 trial for its drug TNX-102 SL to treat major depressive disorder (MDD) in adults. The trial, called HORIZON, will enroll 360 adults across 30 US clinical sites and compare TNX-102 SL against placebo. Tonix aims to advance TNX-102 SL as a novel therapeutic option for the substantial unmet medical need in MDD, which affects over 21 million adults in the US annually.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet